Abstract
Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative syndrome characterized by supranuclear palsy, postural instability, and mild dementia. Neuropathologically, PSP is a four-repeat tauopathy, defined by the accumulation of neurofibrillary tangles and tufted astrocytes. Etiology remains elusive, but genetic background has a key-role in the disease pathogenesis. Recent studies have reported high familial aggregation in PSP patients, and it has been widely demonstrated that Microtuble Associated Protein Tau (MAPT) gene mutations are causative of monogenic autosomal dominant PSP. In sporadic cases, genetic advances have further confirmed the role of MAPT in increasing disease risk, and the H1 MAPT haplotype has been consistently associated with PSP, while the H2 haplotype seems protective. Conversely, no major environmental risk factors have been reported so far. A proper evaluation of known susceptibility factors related to PSP pathogenesis may help in defining neuroprotective therapeutic approaches.
Keywords: Progressive Supranuclear Palsy, Microtuble Associated Protein Tau, Tau, genetics, mutations, polymorphisms, PSP, neurodegenerative syndrome, mild dementia, four-repeat tauopathy
Current Medicinal Chemistry
Title: Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Volume: 18 Issue: 17
Author(s): Barbara Borroni, Chiara Agosti, Enrico Magnani, Monica Di Luca and Alessandro Padovani
Affiliation:
Keywords: Progressive Supranuclear Palsy, Microtuble Associated Protein Tau, Tau, genetics, mutations, polymorphisms, PSP, neurodegenerative syndrome, mild dementia, four-repeat tauopathy
Abstract: Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative syndrome characterized by supranuclear palsy, postural instability, and mild dementia. Neuropathologically, PSP is a four-repeat tauopathy, defined by the accumulation of neurofibrillary tangles and tufted astrocytes. Etiology remains elusive, but genetic background has a key-role in the disease pathogenesis. Recent studies have reported high familial aggregation in PSP patients, and it has been widely demonstrated that Microtuble Associated Protein Tau (MAPT) gene mutations are causative of monogenic autosomal dominant PSP. In sporadic cases, genetic advances have further confirmed the role of MAPT in increasing disease risk, and the H1 MAPT haplotype has been consistently associated with PSP, while the H2 haplotype seems protective. Conversely, no major environmental risk factors have been reported so far. A proper evaluation of known susceptibility factors related to PSP pathogenesis may help in defining neuroprotective therapeutic approaches.
Export Options
About this article
Cite this article as:
Borroni Barbara, Agosti Chiara, Magnani Enrico, Di Luca Monica and Padovani Alessandro, Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease, Current Medicinal Chemistry 2011; 18 (17) . https://dx.doi.org/10.2174/092986711795933722
DOI https://dx.doi.org/10.2174/092986711795933722 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Connectivity in Elderly Controls and AD Patients Using Resting State fMRI: A Pilot Study
Current Alzheimer Research Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Recent Developments in Deception Research
Current Psychiatry Reviews Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Serotonin and its Receptors in the Human CNS with New Findings - A Mini Review
Current Medicinal Chemistry Spirocyclohexadienones as an Uncommon Scaffold for Acetylcholinesterase Inhibitory Activity
Medicinal Chemistry Editorial: (Thematic Issue) Novel Concepts on the Blood-Brain Barrier and Brain Pathology. New Therapeutic Approaches
CNS & Neurological Disorders - Drug Targets The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Effect of Solvents, Drug/Polymer Ratio and Surfactant Concentration on In Vitro Characteristic of Repaglinide Loaded Poly (Meth) Acrylate Nanoparticles
Micro and Nanosystems Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design A Clinician’s Guide to Monoamine Oxidase Inhibitors
Current Psychiatry Reviews Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets